RT @EBRheum: #ACR19 Abst#2878 #ACRbest - Tildrakizumab (IL23i) RCT Good ACR20 (80% v 51%, NNT ~3) regardless of dose; great safety profile…
Tweet Content
#ACR19 Abst#2878 #ACRbest - Tildrakizumab (IL23i) RCT
Good ACR20 (80% v 51%, NNT ~3) regardless of dose; great safety profile. Curiously high PLBO response, expectation bias?
PASI75 phenomenal per usual (80% v 17% plbo, NNT 1-2)
Need IL23/IL17/TNF comparative study!
@RheumNow https://t.co/uEGvsD8KVb
Show on Archive Page
On
Display in Search Results
On